Topoisomerase I remains a target of active interest in the development new anticancer agents because topoisomerase I inhibitors are clearly active and effective anticancer drugs and because the current topoisomerase I inhibitors are molecules that can be improved upon. There are currently camptothecin and non-camptothecin topoisomerase I inhibitors in preclinical and clinical development. Each of these investigational molecules depicted in this book may have properties that lead to improved therapeutic bene ts to patients in future.
Bitte wählen Sie Ihr Anliegen aus.
Rechnungen
Retourenschein anfordern
Bestellstatus
Storno